Semper Paratus Acquisition (NASDAQ:TVGN) Given Buy Rating at D. Boral Capital

Key Points

• The stock of Semper Paratus Acquisition (NASDAQ:TVGN) received a buy rating from D. Boral Capital, with a price target set at $10.00.
• CEO Ryan H. Saadi sold over 1.4 million shares of the company, reducing his stake by 1.22%, while insiders collectively hold 73.24% of the company's stock.
• Institutional investors have increased their positions, with notable investments from Barclays PLC and JPMorgan Chase & Co. during the fourth quarter.

Semper Paratus Acquisition (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price target on the stock.

Semper Paratus Acquisition Trading Up 1.1%

TVGN opened at $1.00 on Monday. The firm has a fifty day moving average price of $1.21 and a 200 day moving average price of $1.21. Semper Paratus Acquisition has a 1 year low of $0.26 and a 1 year high of $3.09.

Insider Buying and Selling at Semper Paratus Acquisition

In related news, CEO Ryan H. Saadi sold 1,438,206 shares of Semper Paratus Acquisition stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $1.23, for a total value of $1,768,993.38. Following the completion of the transaction, the chief executive officer owned 116,814,453 shares in the company, valued at $143,681,777.19. The trade was a 1.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 73.24% of the company's stock.

Institutional Trading of Semper Paratus Acquisition

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC raised its position in Semper Paratus Acquisition by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after acquiring an additional 12,847 shares during the period. Northern Trust Corp raised its holdings in shares of Semper Paratus Acquisition by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock valued at $122,000 after acquiring an additional 13,595 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Semper Paratus Acquisition by 74.2% in the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after acquiring an additional 16,695 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Semper Paratus Acquisition during the fourth quarter worth approximately $55,000. Finally, Nuveen LLC purchased a new position in Semper Paratus Acquisition in the 1st quarter valued at $97,000.

Semper Paratus Acquisition Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.